Guardant Health and Chinese clinical laboratory firm Adicon said on Wednesday that they have signed a strategic partnership under which Adicon has licensed Guardant's tissue and blood-based genomic cancer assays

Bio-Techne said on Wednesday that it has recently received CE marking and launched in Europe its assay for human papillomavirus for use in patients with head and neck cancer.

Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK).

Belgian molecular diagnostics firm Biocartis said on Wednesday that it will develop a molecular test to identify patients with non-small cell lung cancer most likely to respond to AstraZeneca's Tagrisso (osimertinib) treatment.

On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million CNY B+ round of financing.

By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports. While considered uncommon, inherited gene mutations can increase a person’s risk of developing pancreatic cancer.

On May 23, New Horizon Health (6606.HK) and Prenetics Group Limited (NASDAQ: PRE, Prenetics for short) jointly announced a strategic cooperation to promote the listing of cancer early screening product ColoClear in Hong Kong and "going overseas" to Southeast Asia.

Hitachi High-Tech and Invivoscribe on Monday announced a partnership to combine their expertise and technologies to develop molecular diagnostics to diagnose cancer and monitor disease during treatment.

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy

C2i Genomics launches minimal residual disease test across Europe after clearing regulatory hurdles in the EU, UK, and Switzerland.